Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • MedGenome acquires...

    MedGenome acquires Illumina Hiseq X Ten platform to strengthen Genomics Research

    Written by savita thakur thakur Published On 2016-10-15T11:35:12+05:30  |  Updated On 15 Oct 2016 11:35 AM IST
    MedGenome acquires Illumina Hiseq X Ten platform to strengthen Genomics Research

    Bangalore : MedGenome announced that it has purchased the Illumina Hiseq X Ten platform to fuel its genomic research services capability and capacity. MedGenome joins a small number of global players in the genomics research space, and the first one in South-East Asia, to own one of these high throughput Illumina sequencing platforms.


    “We are passionate about improving human health through use of genomics research and insights”, said Mr. Sam Santhosh, Chairman and Global CEO, MedGenome. “We will have these machines operational in India and the US by next month and will be looking forward to collaborating with various large scale genomic projects in the region and abroad.”


    With its high throughput and unprecedented low price per genome, the HiSeq X Ten makes population-scale whole genome sequencing (WGS) an affordable reality. The technology is bringing down the price of Whole Genome and Whole Genome Methylation sequencing to the much anticipated USD 1,000. Affordable sequencing could also have a huge impact in diagnostics.


    “The HiSeq X Ten System is the first and only platform to break the $1000 barrier for high quality human whole genome sequencing” said Tim Orpin, Vice President Asia Pacific, Illumina “We are happy to partner with MedGenome to drive the genomics revolution in India and continue to work towards our vision of unlocking the power of the genome”.


    The possibilities of the large scale genetic sequencing projects and the innovative genomic research that it can enable to better understand complex human diseases is well understood by the research community. The HiSeq X10 machines continue to break down barriers in traditional sequencing technologies, and in redefining the cost of whole genome sequencing. It facilitates the path breaking research that is taking place across the world in the form of population-scale genome sequencing projects. This high performing system promises to accelerate a deeper understanding of genetic disorders to allow us to find ways to better tackle them.

    AcquisitiongenomicsIllumina HiseqMedGenomeMr Sam SanthoshWGSwhole genome sequencing
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok